Szingapúr - angol - HSA (Health Sciences Authority)

gsk consumer healthcare singapore pte. ltd. - diclofenac potassium - tablet, film coated - 12.5 mg - diclofenac potassium 12.5 mg

Szingapúr - angol - HSA (Health Sciences Authority)

gsk consumer healthcare singapore pte. ltd. - terbinafine hcl - spray - 10 mg/g - terbinafine hcl 10 mg/g

Szingapúr - angol - HSA (Health Sciences Authority)

gsk consumer healthcare singapore pte. ltd. - orlistat, milled - capsule - 60.00mg - orlistat, milled 60.00mg

Szingapúr - angol - HSA (Health Sciences Authority)

gsk consumer healthcare singapore pte. ltd. - (center) nicotine - gum, chewing - 2mg - (center) nicotine 2mg

Szingapúr - angol - HSA (Health Sciences Authority)

gsk consumer healthcare singapore pte. ltd. - (center) nicotine - gum, chewing - 4mg - (center) nicotine 4mg

Európai Unió - angol - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - orlistat - obesity - antiobesity preparations, excl. diet products - alli is indicated for weight loss in adults who are overweight (body mass index, bmi, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

Európai Unió - angol - EMA (European Medicines Agency)

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

Egyesült Államok - angol - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Izrael - angol - Ministry of Health

gsk consumer healthcare, israel ltd - ipratropium bromide; xylometazoline hydrochloride - nasal spray, solution - ipratropium bromide 0.6 mg/ml; xylometazoline hydrochloride 0.5 mg/ml - ipratropium bromide - symptomatic treatment of nasal congestion and rhinorrhea in connection with common cold in adults.

Izrael - angol - Ministry of Health

gsk consumer healthcare, israel ltd - dimethindene maleate - gel - dimethindene maleate 0.1 %w/w - dimetindene - urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.